Simulations Plus (FRA:SD3) Research & Development: €8.03 Mil (TTM As of Feb. 2026)


FRA:SD3 Simulations Plus Inc FRA:SD3
67 GF Score
Price €15.80
GF Value €32.93
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Simulations Plus Research & Development?

Simulations Plus FRA:SD3 67 Research & Development is €8.03 Mil as of Feb. 2026. GuruFocus rates FRA:SD3 with a GF Score™ of 67/100 and a GF Value™ of €32.93 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Simulations Plus's Research & Development for the three months ended in Feb. 2026 was €2.94 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was €8.03 Mil.

Simulations Plus  (FRA:SD3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Simulations Plus Research & Development Related Terms

Simulations Plus Research & Development Historical Data

* Premium members only.

The historical data trend for Simulations Plus's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simulations Plus Research & Development Chart

Simulations Plus Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 3.17 4.13 5.22 5.91

Simulations Plus Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 1.08 1.44 2.58 2.94
FRA:SD3
67GF Score
Simulations Plus Inc FRA:SD3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simulations Plus Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €8.03 Mil mean?
Simulations Plus (FRA:SD3) has a Research & Development of €8.03 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on Simulations Plus and its competitors.
Is Simulations Plus' Research & Development too high?
Simulations Plus' current Research & Development is €8.03 Mil. Overall, Simulations Plus has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Research & Development compare to TBRG and CARL?
Simulations Plus' Research & Development of €8.03 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Simulations Plus and its competitors. Simulations Plus's current Research & Development is €8.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (FRA:SD3) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.93, compared to a current price of €15.80 — trading 52% below its estimated fair value. The current Research & Development is €8.03 Mil. Simulations Plus' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current Research & Development is €8.03 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simulations Plus (FRA:SD3) Overvalued in 2026?

Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued. The current stock price of €15.80 is trading 52% below its estimated GF Value™ of €32.93. GuruFocus considers Simulations Plus to be Significantly Undervalued.

Key valuation signals for FRA:SD3:

  • Research & Development: €8.03 Mil
  • GF Value™: €32.93 vs. price of €15.80 (52% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simulations Plus Business Description

Other Exchanges SLP:USA
Address 800 Park Offices Drive, Suite 401, Research Triangle Park, Lancaster, NC, USA, 27709
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
67GF Score

Get the complete analysis for FRA:SD3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.80
Price
€32.93
GF Value